It recently completed the acquisitions of Sierra Oncology (for $1.9 billion) as well as BELLUS Health (for around $2 billion). Through these deals, Walmsley’s company aims to address the medical ...

GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in the next year. In an interview at the JP Morgan Healthcare Conference in San Francisco ...

(Bloomberg) -- GSK Plc’s Chief Executive Officer Emma Walmsley is looking to ... you haven’t seen tariffs being brought to bear on health care,” Walmsley said. “We are very focused on ...

GlaxoSmithKline’s new CEO Emma Walmsley is set to outline her vision ... in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl ...

Walmsley says the global drugmaker is at last ready to deliver results. She completed the final step of that overhaul this summer, spinning off GSK’s $13 billion consumer health unit—Europe ...

GSK said it will pay CureVac 400 million euros ($429.44 million) upfront and up to an additional 1.05 billion euros ($1.13 billion) in development, regulatory and sales milestones as well as ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines. While GSK already agreed to multiple deals in ...